Search

Your search keyword '"Tobe, Sheldon"' showing total 108 results

Search Constraints

Start Over You searched for: Author "Tobe, Sheldon" Remove constraint Author: "Tobe, Sheldon" Publication Type Magazines Remove constraint Publication Type: Magazines
108 results on '"Tobe, Sheldon"'

Search Results

2. Renal denervation for uncontrolled hypertension

3. Ligne directrice C-CHANGE pour l'harmonisation des lignes directrices nationales de prevention et de prise en charge des maladies cardiovasculaires en contexte de soins primaires au Canada : mise a jour 2022

4. Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update

5. Oral curcumin in elective abdominal aortic aneurysm repair: a multicentre randomized controlled trial

6. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update

7. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes

8. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 update

9. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

10. Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes

11. Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE initiative

12. Guidelines for the management of chronic kidney disease

13. Effect of nurse-directed hypertension treatment among First Nations people with existing hypertension and diabetes mellitus: the Diabetes Risk Evaluation and Microalbuminuria (DREAM 3) randomized controlled trial

14. Applying the 2005 Canadian Hypertension Education Program recommendations: 5. Therapy for patients with hypertension and diabetes mellitus

16. Bioavailability of oral curcumin

17. Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD)

19. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

20. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

21. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children

22. Hypertension Canada’s 2020 Evidence Review and Guidelines for the Management of Resistant Hypertension

23. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

24. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

25. Guideline Alignment in Related Areas

26. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

28. The Influence of Marital Adjustment on 3-Year Left Ventricular Mass and Ambulatory Blood Pressure in Mild Hypertension

30. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children

31. Thresholds and Targets for Hypertension Management in Adults With Type 2 Diabetes Should Remain at 130/80 mmHg: What's the Evidence?

33. Steady-State Pharmacokinetics of Oral Ciprofloxacin in Continuous Cycling Peritoneal Dialysis Patients: Brief Report

34. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults

35. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes

36. Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries

38. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

39. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events

40. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

41. Preventing Cardiovascular and Renal Disease in Canada's Aboriginal Populations

42. The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

43. A New Algorithm for the Diagnosis of Hypertension in Canada

44. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD

45. Contemporary Use of β-Blockers: Clinical Relevance of Subclassification

46. Combining Other Antihypertensive Drugs With β-Blockers in Hypertension: A Focus on Safety and Tolerability

47. β-Blockers in Hypertension: Studies and Meta-analyses Over the Years

48. The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

49. Renal Denervation Therapy for the Treatment of Resistant Hypertension: A Position Statement by the Canadian Hypertension Education Program

50. The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

Catalog

Books, media, physical & digital resources